UNICANCER: Breast Neoplasms trials

The registry lists 59 Breast Neoplasms studies with UNICANCER as lead sponsor. 14 are open to participants now and 1 have results posted.

Phase 1 2Phase 2 24Phase 3 15No phase 18(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.Not yet recruitingNCT07717450Phase 3
• Skipping Hormone Therapy in Low-Risk Early Breast CancerRecruitingNCT07661927Phase 2
• Antibody-based PET Imaging and Treatment Response in Breast Cancer Treated With an Antibody-drug Conjugate.Not yet recruitingNCT07294430Phase 2
• Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant RibociclibRecruitingNCT07237256Phase 3
• Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast CancerNot yet recruitingNCT07151586Phase 2
• Evaluation of an Online Intervention to Educate Women at High Risk of Breast Cancer on How to Help Reduce Their Risk.RecruitingNCT07120087Not applicable
• Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic TestsRecruitingNCT07106632Phase 3
• Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd TherapyEnrolling by invitationNCT06680596Phase 2
• Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast CancerRecruitingNCT06606730Phase 3
• Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.RecruitingNCT06450314Phase 2
• Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBCRecruitingNCT06078384Phase 2
• Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low RiskRecruitingNCT05297617Phase 2
• Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008RecruitingNCT03275311
• Chronic Toxicities Related to Treatment in Patients With Localized CancerRecruitingNCT01993498Not applicable
• Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast CancerCompletedNCT00630032Phase 3Results posted
• Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or RibociclibTerminatedNCT05625087Phase 2
• Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast CancerActive, not recruitingNCT05552001Phase 3
• Patient's Choice in the Reduction of Their Treatment in Women Over 65 Year With Breast CancerCompletedNCT05058196Not applicable
• Concordance of the IHC4 Score Performed in Local or Central Laboratory to Endopredict in ER+/HER2- Breast CancerCompletedNCT04246606
• Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast CancerActive, not recruitingNCT04158362Phase 3
• Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers AnalysisCompletedNCT04132960Phase 2
• Radiotherapy Omission in Low Risk Ductal in Situ Carcinoma BreastActive, not recruitingNCT03878342Not applicable
• Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer PatientsActive, not recruitingNCT03870919Not applicable
• SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast CancerTerminatedNCT03386162Phase 2
• Investigation of Tumour Spectrum of Germline Mutations in Breast and Ovarian Cancer Genes.Active, not recruitingNCT03246841Not applicable
• Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only MetastasesActive, not recruitingNCT03143322Not applicable
• Hypofractionated vs Standard Radiotherapy in Breast Cancer With an Indication for Regional Lymph Node Irradiation About Lymphedema OccurrenceActive, not recruitingNCT03127995Not applicable
• Assessment of Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in ER-positive, Her2-negative Early Breast CancerWithdrawnNCT03080428Not applicable
• PAlbociclib and Circulating Tumor DNA for ESR1 Mutation DetectionCompletedNCT03079011Phase 3
• Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant ExposureCompletedNCT02997995Phase 2
• Prospective Study Assessing EndoPredict® Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in Patients With ER-positive, Her2-negative Early Breast CancerCompletedNCT02773004Not applicable
• Phase I Evaluating the Combination of Ribociclib+Capecitabine in Locally Advanced/Metastatic Breast Cancer HER2 NegativeCompletedNCT02754011Phase 1
• A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic SignatureCompletedNCT02505048Phase 2
• Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR InhibitorCompletedNCT02444390Not applicable
• Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal WomenCompletedNCT02400567Phase 2
• Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A StatusCompletedNCT02339532Phase 2
• Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast CancerCompletedNCT02324088Phase 3
• SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerActive, not recruitingNCT02299999Phase 2
• Abiraterone Acetate in Molecular Apocrine Breast CancerCompletedNCT01842321Phase 2
• Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab and Paclitaxel in Patients With Metastatic Breast CancerCompletedNCT01745757
• Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine TreatmentCompletedNCT01564056Phase 3
• High Throughput Technologies to Drive Breast Cancer Patients to Specific Phase I/II Trials of Targeted AgentsCompletedNCT01414933
• Evaluating Lapatinib + Capecitabine in Patients Aged 70 and Over With HER2 Metastatic Breast Cancer.CompletedNCT01262469Phase 2
• Standard or Hypofractionated Radiotherapy Versus Accelerated Partial Breast Irradiation (APBI) for Breast CancerActive, not recruitingNCT01247233Not applicable
• Lapatinib Ditosylate and Capecitabine in Treating Patients With Stage IV Breast Cancer and Brain MetastasesCompletedNCT00967031Phase 2
• Efficacy and Tolerance Study of Bevacizumab in Her2- Inflammatory Breast Cancer PatientsCompletedNCT00820547Phase 2
• Trastuzumab With or Without Everolimus in Treating Women With Breast Cancer That Can Be Removed By SurgeryTerminatedNCT00674414Phase 2
• Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 MutationCompletedNCT00673335Phase 3
• Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast CancerCompletedNCT00629616Phase 2
• Positron Emission Tomography Using 3'-Deoxy-3'-(18F) Fluorothymidine in Treating Women With Locally Advanced Cancer in One Breast Who Are Receiving ChemotherapyCompletedNCT00534274Not applicable
• Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast CancerCompletedNCT00513058Phase 1
• Doxorubicin and Cyclophosphamide in Treating Older Women With Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By SurgeryCompletedNCT00424203Phase 2
• Radiation Therapy in Treating Older Women Who Are Undergoing Surgery for Stage I or Stage II Breast CancerCompletedNCT00104702Phase 2
• Docetaxel in Treating Older Women With Metastatic Breast CancerTerminatedNCT00104624Phase 2
• Combination Chemotherapy in Treating Women With Stage I Breast CancerCompletedNCT00055679Phase 3
• Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast CancerCompletedNCT00054587Phase 3
• Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast CancerTerminatedNCT00053911Phase 3
• Diagnostic Study to Identify Sentinel Lymph Nodes in Women With Stage I or Stage II Breast CancerTerminatedNCT00003654Not applicable
• High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Locally Recurrent or Metastatic Breast CancerCompletedNCT00002870Phase 3